ART Advanced Research Technologies Launches Optix MX3 Molecular Imaging System at WMIC2009
September 23 2009 - 7:05AM
Marketwired
ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a
Canadian medical device company and a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries,
today unveiled a new generation of its optical molecular imaging
system, called Optix® MX3, at the Industry Workshop opening event
of the World Molecular Imaging Congress. The event is being held
this year in Montreal, Canada, from September 23 to 26. ART is also
featuring the Optix® MX3, as well as its SoftScan® and Fenestra®
product offering, as an exhibitor at the event (booth #301), in the
Exhibit Hall of the Palais des congres de Montreal.
"The Optix MX3 addresses a real market need as customers in the
drug discovery and development process continue to demand tools
providing an extensive qualitative and quantitative data set in
small animal research, while ensuring reliability and performance
for applications requiring longitudinal studies," said Sebastien
Gignac, Chairman & CEO of ART. "While products currently on the
market can only detect the intensity of the signal coming from a
mouse specimen, the Optix MX3 system quite effectively exploits the
power of our time domain technology to move beyond this type of
signal measurement to obtain much richer and complex data. Indeed,
with our Optix MX3, scientists are actually able to gain confidence
in the exactitude of their results, by accurately differentiating
various compound types and determining their concentration and
depth precisely."
"We are excited to announce that the Optix MX3 is now available
through our dedicated sales teams in North America and Europe, as
well as our regional distribution partners in Italy, India, Japan,
Korea and the United Kingdom," said Dino DiCamillo, Vice President,
Global Sales & Marketing, of ART.
The compact Optix MX3 system offers the highest sensitivity
among fluorescent systems in the preclinical market and unique
optical molecular imaging features. The completely re-engineered
and redesigned Optix platform will mean an increase in performance
level, entail savings in manufacturing costs, and will incorporate
new technological market drivers, such as the ability to image red
fluorescent proteins, Q-dots, and the complete spectrum ranging
from 450 nm to 850 nm with the support of a state-of-the-art
tunable laser.
Using ART's proven and proprietary time-domain technology, which
allows measurement of the light's time of arrival, Optix MX3 is
sensitive enough to detect target signals deep within the organs of
small animals. Unique to the Optix MX3 is the ability to recover
fluorescence lifetime, which can be used to separate and quantify
fluorescent probe distributions depending on their respective
biochemical environment. Also part of the Optix MX3 is the CT
fusion software package allowing researchers to export the scan
obtained using Optix MX3 in DICOM format, and fuse it with micro-CT
for a full 3D anatomical reference.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix® optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan® optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra®
line of molecular imaging contrast products provides image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART
is commercializing some of these products in a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2008, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Dino DiCamillo
Vice President, Global Sales and Marketing, Preclinical Imaging
ddicamil@art.ca ART Advanced Research Technologies Inc. Jacques
Bedard Chief Financial Officer 514-832-0777 jbedard@art.ca
www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024